{"classes":[{"categories":[{"measurements":[{"comment":"1 trough concentrations that was reported below the limit of quantitation were treated as missing for the concentration summaries.","groupId":"OG000","spread":"NA","value":"NA"}]}],"title":"Week 0"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"57","value":"23.5"}]}],"title":"Week 2"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"60","value":"44.1"}]}],"title":"Week 6"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"46","value":"60.2"}]}],"title":"Week 12"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"40","value":"63.2"}]}],"title":"Week 18"}],"denoms":[{"counts":[{"groupId":"OG000","value":"195"}],"units":"Participants"}],"description":"PK Cmin of Ramucirumab Blood samples were collected at specified time points, and in the event of an infusion-related reaction, for assessment of ramucirumab serum concentrations.","dispersionType":"Geometric Coefficient of Variation","groups":[{"description":"8 mg/kg ramucirumab administered as an IV injection on day 1 of each 14 day cycle. Participants may continue treatment until discontinuation criteria are met.","id":"OG000","title":"Ramucirumab + BSC"}],"paramType":"GEOMETRIC_MEAN","populationDescription":"All randomized participants who received at least one dose of study drug.","reportingStatus":"POSTED","timeFrame":"Predose, Weeks 2, 6, 12 and 18, Day 1; Up to 3 Days Before Infusion (14-Day Cycles)","title":"Pharmacokinetics (PK): Minimum Serum Concentration (Cmin) Before 2nd, 4th, 7th, and 10th Infusion","type":"SECONDARY","unitOfMeasure":"nanogram/milliliter (ng/mL)"}